Cover Image

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial

Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK+ non-smallcell lung cancer (NSCLC) patients to over five years. In particular, second-generation ALK TKI have demonstrated superiority compared to the first-generation compo...

Full description

Saved in:
Bibliographic Details
Main Authors: Christopoulos, Petros (Author) , Bozorgmehr, Farastuk (Author) , Brückner, Lena Marie (Author) , Chung, Inn (Author) , Krisam, Johannes (Author) , Schneider, Marc (Author) , Stenzinger, Albrecht (Author) , Eickhoff, Regina (Author) , Mueller, Daniel W. (Author) , Thomas, Michael (Author)
Format: Article (Journal)
Language:English
Published: 28 June 2021
In: BMC cancer
Year: 2021, Volume: 21, Pages: 1-10
ISSN:1471-2407
DOI:10.1186/s12885-021-08460-w
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-021-08460-w
Get full text
Author Notes:Petros Christopoulos, Farastuk Bozorgmehr, Lena Brückner, Inn Chung, Johannes Krisam, Marc A. Schneider, Albrecht Stenzinger, Regina Eickhoff, Daniel W. Mueller and Michael Thomas
Description
Summary:Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK+ non-smallcell lung cancer (NSCLC) patients to over five years. In particular, second-generation ALK TKI have demonstrated superiority compared to the first-generation compound crizotinib and are meanwhile standard first-line treatment. However, clinical courses of individual patients vary widely, with secondary development of drug resistance and intracranial progression remaining important problems. While these limitations highlight the need for better disease monitoring and additional therapeutic tools, molecular tumor features are increasingly recognized as crucial determinants of clinical outcome. This trial aims to optimize management of ALK+ NSCLC by analyzing the efficacy of second-generation ALK inhibitors in conjunction with deep longitudinal phenotyping across two treatment lines.
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-021-08460-w

Similar Items